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CONSENSUS STATEMENT
Recommendations from the European Commission Initiative
on Breast Cancer for multigene testing to guide the use of
adjuvant chemotherapy in patients with early breast cancer,
hormone receptor positive, HER-2 negative
Paolo Giorgi Rossi1, Annette Lebeau2, Carlos Canelo-Aybar3,4, Zuleika Saz-Parkinson 5,6, Cecily Quinn7, Miranda Langendam8,
Helen Mcgarrigle9, Sue Warman10, David Rigau3, Pablo Alonso-Coello3, Mireille Broeders11,12, Axel Graewingholt13,
Margarita Posso3,14,15, Stephen Duffy 16, Holger J. Schünemann17 and the ECIBC Contributor Group
BACKGROUND: Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is crucial to
optimise adjuvant treatment. Despite the common practice of using multigene tests to predict recurrence, existing
recommendations are inconsistent. Our aim was to formulate healthcare recommendations for the question “Should multigene tests
be used in women who have early invasive breast cancer, hormone receptor-positive, HER2-negative, to guide the use of adjuvant
chemotherapy?”
METHODS: The European Commission Initiative on Breast Cancer (ECIBC) Guidelines Development Group (GDG), a multidisciplinary
guideline panel including experts and three patients, developed recommendations informed by systematic reviews of the evidence.
Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision frameworks were used. Four
multigene tests were evaluated: the 21-gene recurrence score (21-RS), the 70-gene signature (70-GS), the PAM50 risk of recurrence
score (PAM50-RORS), and the 12-gene molecular score (12-MS).
RESULTS: Five studies (2 marker-based design RCTs, two treatment interaction design RCTs and 1 pooled individual data analysis
from observational studies) were included; no eligible studies on PAM50-RORS or 12-MS were identified and the GDG did not
formulate recommendations for these tests.
CONCLUSIONS: The ECIBC GDG suggests the use of the 21-RS for lymph node-negative women (conditional recommendation, very
low certainty of evidence), recognising that benefits are probably larger in women at high risk of recurrence based on clinical
characteristics. The ECIBC GDG suggests the use of the 70-GS for women at high clinical risk (conditional recommendation, low certainty
of evidence), and recommends not using 70-GS in women at low clinical risk (strong recommendation, low certainty of evidence).
British Journal of Cancer (2021) 124:1503–1512; https://doi.org/10.1038/s41416-020-01247-z
BACKGROUND
Breast cancer is the most frequently diagnosed cancer among
women.1 In the European Union, including UK, 404,920 women
were diagnosed with breast cancer and 98,755 died because
of this disease in 2018.2 Hormone receptor (HoR)-positive
(i.e. oestrogen receptor (ER)- and/or progesterone receptor
(PR)-positive), human epidermal growth factor receptor 2
(HER2)-negative breast cancer represents about 70% of breast
cancer diagnosed in western countries.3 At the time of diagnosis,
around 60% of this type of cancer has not spread to lymph
nodes,3 and approximately 15% of these women will develop a
recurrence within 10 years if treated with adjuvant endocrine
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therapy alone.4,5 The risk of recurrence could be reduced by the
addition of chemotherapy.5 However, given the relatively low risk of
recurrence and the partial effectiveness of chemotherapy in these
women, most would be over-treated if all received chemotherapy.
The same rationale would apply to women with HoR-positive,
HER2-negative invasive breast cancer with 1–3 positive lymph
nodes.6 Several prognostic factors, including clinical-pathological
features such as age, tumour size, percentage of ER- and PR-positive
cells as well as Ki67-index,7–9 predict the risk of recurrence and can
help identify women who would benefit the most from
chemotherapy. Although these factors have been shown to
discriminate different prognostic groups, they showed no or
minimal predictive value on the response to chemotherapy.10
In the last 15 years, different tests have been developed to
stratify patients with early breast cancer into different risk of
recurrence groups by analysing the activity of various genes.
Although these multigene tests use diverse techniques (RT-PCR,
microarray, and others) and diverse target gene combinations,
they all focus on genes involved in cell proliferation. The tests
provide recurrence risk profiles categorised in different ways.
Some tests have been explicitly proposed to provide additional
information to clinical-pathological features, as the 12-MS and the
PAM50-RORS. Based on the results of the MINDACT trial,6 the
application of the 70-GS also takes into account clinical prognostic
characteristics, while the 21-RS has been proposed to substitute
clinical risk-based treatment decisions.
The European Commission Initiative on Breast Cancer (ECIBC)
aims to provide evidence-based recommendations for screening
and diagnosis of breast cancer.11 The Guidelines Development
Group (GDG) of the ECIBC prioritised a clinical question on the use
of multigene tests to guide the use of adjuvant chemotherapy in
HoR-positive, HER2-negative and lymph node-negative or up to 3
lymph nodes-positive invasive breast cancer. Four multigene tests,
used to stratify women with breast cancer into different groups
according to recurrence risk,12–17 are included in the clinical
question (Supplementary Table 1): 21-RS (Oncotype DX, Genomic
Health Inc), 12-MS (EndoPredict, Myriad Genetics Inc), PAM50-
RORS (Prosigna test, NanoString Technologies Inc.), and 70-GS
(MammaPrint; Agendia Inc). Direct comparison between different
tests is beyond the scope of these recommendations.
METHODS
Structured question and outcome prioritisation
The clinical question “Should multigene tests be used in patients
who have HoR-positive, HER-2 negative, lymph node-negative or up
to 3 lymph nodes-positive invasive breast cancer to guide the use of
adjuvant chemotherapy” was structured following the Population,
Intervention, Comparison and Outcomes (PICO) format (Table 1).
The outcomes were also prioritised by the GDG using a nine-point
scale (7 to 9 critical; 4 to 6 important; 1 to 3 of limited importance),
as suggested by the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach.11,18 The GDG
decided not to attempt any head-to-head comparisons between
the different tests.
Systematic review
Data sources and searches. MEDLINE (May 2018), EMBASE (May
2018) and CENTRAL (May 2018) databases were searched, using
pre-defined algorithms, for both systematic reviews and individual
studies (Supplementary Table 2); this original search was
continuously run up to October 2018. Lists of references of the
included studies were reviewed and members of the GDG were
requested to provide additional studies.
Study selection. Randomised controlled trials (RCT) and cohort
studies (including pooled analyses of studies), either from
prospective or retrospective analysis, of stored specimen samples
were included as long as they applied any of the four tests as
predictive markers for guiding the use of adjuvant chemotherapy
(Supplementary Fig. 1)
A predictive marker identifies the differential benefit of a
treatment based on the marker status. Thus, we included the
following assessment approaches: (a) Marker-based strategy design:
patients are assigned to a treatment arm depending on whether
they received treatment (i.e. endocrine therapy or endocrine plus
chemotherapy) according to the test results or according to usual
clinical practice. The predictive value is assessed by comparing the
outcomes from the testing-based arm versus the non-testing arm;
(b) Treatment interaction design: patients are divided into groups
based on the marker status (i.e. high and low marker status). Then
they are allocated to receive endocrine therapy or endocrine
treatment plus chemotherapy. The predictive value is assessed by
observing the relative efficacy of treatment differences between
marker status and treatment assignments.
Studies that only reported prognosis data based on marker
status (without considering differential treatment effect), indivi-
dual observational studies, abstracts or conference communica-
tions not published as full text articles, and articles published in a
language other than English were excluded.
With respect to economic evidence, cost-utility, cost-benefit, and
cost-consequences, analyses were included if conducted within
clinical trials, as well as observational and modelling studies,
published in English during the last decade (Supplementary Table 3).
Table 1. Structured clinical questions.
Population Intervention Comparison Outcomes
Patients with hormone receptor-positive,
HER2- negative, lymph node-negative or
up to 3 lymph nodes-positive invasive
breast cancer.
70-gene signature to decide chemotherapy:
women with low clinical risk do not receive
chemotherapy independently from 70-gene
signature; women with high clinical risk will
receive chemotherapy only if at high
genomic risk
• According to the considered clinical trial
designs the comparison would be either:
• All patients receive chemotherapy
• All patients with low clinical risk do not
receive chemotherapy and those with high
clinical risk subgroup receive
chemotherapy.
Direct comparisons between the different






• Quality of life.
21-gene recurrence score to decide
chemotherapy, in two alternative scenarios:
• Women with low or intermediate genomic risk
will not receive chemotherapy, women with
high genomic risk will;
• Only women with high clinical risk will be tested
for genomic risk and receive chemotherapy if
genomic risk is high; women with low clinical
risk will not receive chemotherapy.
Initially PICOs covered four multigene tests, but two of them, the PAM50 risk of recurrence score (RORS) and 12-gene molecular score (12-MS), were excluded
because of study selection criteria. These selection criteria allowed no direct comparison between the different multigene tests.
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After a calibration process, each reviewer (CCA and KP) assessed
titles and abstracts for eligibility. Subsequently, two reviewers (CCA
and KP), independently, reviewed the full text of all the pre-selected
references. Discrepancies were solved either by consensus or with
the help of a third reviewer (DR) (Supplementary Fig. 2 and
Supplementary Table 4).
Data extraction and risk of bias assessment. Two reviewers (CCA
and KP) independently assessed risk of bias and extracted the
following information from each study: first author, year of
publication, country, study design, inclusion and exclusion criteria,
number of patients, age, participants’ characteristics and priori-
tised outcomes.
The risk of bias of the included RCTs was assessed using the
Cochrane Risk of Bias tool for randomised trials.19 Cohort studies
were assessed with the “Risk Of Bias In Non-randomised Studies -
of Interventions-I” (ROBINS-I) tool.20 For economic evaluations, one
reviewer (MP) screened the search results and used the NICE
methodology checklist to assess applicability and methodological
limitations.21 Studies with poor applicability and/or high risk of
bias were excluded (Supplementary Fig. 2).
Data analysis. Descriptive statistics were used to summarise the
characteristics of the included patients across studies. The effect
measures for prioritised outcomes and their corresponding 95%
confidence intervals (CIs) were reported as presented in individual
studies.
Certainty of the evidence. The certainty of evidence per outcome
and overall certainty was rated using the GRADE approach. For
each recommendation, the GDG received a Summary of Findings
(SoF) table and a first draft of an evidence to decision framework
(EtD).22
Comparison scenarios and modelling
A simple deterministic decision tree model without discounting was
built by PGR with input from the rest of the GDG to estimate the
downstream consequences of testing patients with the multigene
tests versus different scenarios of usual care (Supplementary
Fig. 3). For the 21-RS, the general model assumptions were: the
population of eligible women was divided into the three risk
groups, as reported in the TAILORx trial at recruitment until 2008
(14% low risk of recurrence, 68% intermediate, 18% high).23 Rate
of events, observed in the RCTs, were applied to the simulated
usual care arms. Clinical risk of recurrence was classified as low
and high according to the modified AdjuvantOnline!Score.24,25
Results are based on a fixed observation time of 10 years.
Two strategies for implementing the multigene test to guide
the use of adjuvant chemotherapy were considered as interven-
tions (Supplementary Fig. 3a):
1. All women would undergo multigene testing and adjuvant
chemotherapy would be given accordingly (only to those
classified in the high genomic risk group, i.e. with a
score ≥26).
2. Only women with high clinical risk would undergo multi-
gene testing, and only those with high genomic risk would
receive chemotherapy. Women with low clinical risk would
not receive it.
Two scenarios were considered as usual care comparators (“C”
of the PICO framework) (Supplementary Fig. 3b):
1. All women would be referred to adjuvant chemotherapy
(assuming 18.4% would not comply, i.e. the proportion of
women not receiving chemotherapy among those assigned
to the treatment arm in TAILORx).23
2. Women would receive adjuvant chemotherapy only if the
clinical risk is high. The model assumes that women with
low clinical and high genomic risk, as well as those with low
clinical and low genomic risk, do not benefit from adjuvant
chemotherapy. For sensitivity analyses, in women of low
clinical and high genomic risk, two different assumptions
were used to estimate the benefits: (a) The advantage of
receiving adjuvant chemotherapy is equivalent to that
observed in the MINDACT trial6 at five years, and the effect
is maintained at 10 years; (b) the advantage from adjuvant
chemotherapy is equivalent to that observed by Paik and
colleagues26 for all women at high genomic risk, indepen-
dent of their clinical risk. Distributions of the clinical risk
within the multigene risk strata are those reported in the
TAILORx trial.23
For the 70-GS, we focused only on comparing strategy 2 with
scenario 2 in which women at high clinical risk would be tested
and/or treated, because the evidence from the MINDACT trial
indicates a very small benefit, if any, from adjuvant chemotherapy
in women with low clinical risk, independent of their genomic
risk.6
Evidence to decision and recommendation formulation
The process the ECIBC GDG used to formulate recommendations
has been described in a dedicated article published elsewhere.11
In brief, a subgroup of GDG members including experts on the
topic and an informed patient (the so-called PICO responsible
unit), took primary responsibility for the review and completion of
the first draft of the SoF tables and the EtD frameworks,
conducted initially by the systematic review team. The frameworks
were used in the meetings to help the complete GDG formulate
the recommendations. Subsequently they were reviewed by a
technical team from the Joint Research Centre, the PICO
responsible unit and the systematic review team. Finally, the
recommendations and frameworks were approved by the GDG.
RESULTS
Included studies
We included five studies (Supplementary Fig. 1): two RCTs,6,23 two
secondary analyses of stored tissue blocks collected from former
parent clinical trials26,27 and one pooled analysis of observational
studies12 from four previously reported validation studies,
including unpublished data (Supplementary Table 5).28–30
21 gene recurrence score
Treatment interaction design studies. Paik and colleagues26
provided estimates for distant recurrence free survival in patients
with lymph node-negative breast cancer stratified into three levels
of the 21-RS risk groups. Adding chemotherapy to endocrine
therapy, compared to endocrine therapy alone, may have a
different effect on recurrence across groups, i.e. a larger effect in
women with higher 21-RS, but the evidence is very uncertain:
hazard ratio (HR) of 1.31 (95% CI 0.46–3.78), 0.61 (95% CI
0.24–1.59) and 0.26 (95% CI 0.13–0.53) in low, intermediate and
high risk groups, respectively (Supplementary Table 6).
Albain and colleagues27 included stored tumour specimens for
genomic testing of postmenopausal women with HoR-positive,
node-positive breast cancer. They performed an analysis adjusted
by the number of positive nodes that suggests no benefit for
chemotherapy on disease free survival (DFS) in the low genomic
risk group (HR= 1.02; 95% CI 0.54–1.93) and a potential advantage
in the high genomic risk (HR= 0.59, 95% CI 0.35–1.01) (Supple-
mentary Table 6). The authors refer similar results for overall
survival (OS).
Marker-based strategy. Sparano and colleagues23 provided
results for several disease-free survival (DFS)-related outcomes
among women with an intermediate genomic risk group (11 to 26
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risk score) allocated to either endocrine therapy alone or
chemotherapy plus endocrine therapy. The as-treated results
suggest little to no difference in the risk of recurrence with
chemotherapy plus endocrine therapy for invasive DFS (HR 1.14;
95% CI 0.99–1.31). For distant metastases, local recurrence and OS,
similar results were observed (Supplementary Table 6).
70-GS
Treatment interaction design studies. Knauer and colleagues12
described results from a pooled database analysis with a median
follow-up time of 7.1 years. Patients with a low and high genomic
risk who received chemotherapy may have a lower risk of
recurrence than those with endocrine therapy alone, but the
evidence is very uncertain (HR 0.26; 95% CI 0.03–2.02 and HR 0.35;
95% CI 0.17–0.71, respectively). The results for mortality were
consistent with the observed pattern of the risk of recurrence but
the evidence was also very uncertain (HR 0.58; 95% CI 0.07–4.98;
HR 0.21; 95%CI 0.07–0.59, respectively) (Supplementary Table 7).
Marker-based strategy. Cardoso and colleagues6 reported DFS
and OS among patients in the clinical/genomic discordant-risk
groups which were allocated to receive either chemotherapy in
addition to endocrine therapy or endocrine therapy alone.
Women with high clinical risk and low genomic risk may have
an increase of DFS (HR 0.64; 95% CI 0.43–0.95), of distant
metastases free survival (HR 0.65; 95% CI 0.38–1.10) and of OS (HR
0.63; 95% CI 0.29–1.37) (Supplementary Table 7). The group of low
clinical risk and high genomic risk showed imprecise effects and
uncertain evidence for DFS (HR 0.74; 95% CI 0.40–1.39), distant
metastases free survival (HR 0.90; 95% CI 0.40–2.01) and OS (HR
0.72; 95% CI 0.23–2.24).6
Modelling for predicting impact of testing on patient’s outcomes
Depending on the different treatment scenarios (all women are
referred to chemotherapy or only women with high clinical risk are
treated with chemotherapy) and genetic testing strategies (genetic
testing carried out in all women or testing only those with high
clinical risk), the number of women who avoid chemotherapy by
using the 21-RS would change from more than 600 to about 200.
Survival outcomes did not change substantially (Table 2) for the 21-
RS based on the benefits from adding chemotherapy in the
MINDACT trial.6 However, on the assumption that all women with
high genomic score would obtain the same benefits from adding
chemotherapy as observed by Paik and colleagues,26 independently
from their clinical risk, the intervention could potentially prevent 37
distant metastases compared to a scenario in which only women
with high clinical risk would be treated with chemotherapy.
On the other hand, we considered for the 70-GS a two-step
strategy according to the results of the MINDACT trial, testing only
women with high clinical risk.6 Consequently, the only scenario
considered was one in which only high-risk women would receive
chemotherapy (Table 3). The use of the 70-GS would result in an
avoidance of chemotherapy in about 230 women out of 1000
associated with small increase of recurrences.
Results from the systematic review of economic evidence
From the primary literature search and from the two identified
systematic reviews,31,32 12 cost-effectiveness evaluations were
identified (Supplementary Fig. 2 and Supplementary Table 4).33–44
The GDG agreed that these economic evaluations used models
that were not directly applicable to the clinical question of
interest. Therefore, cost-effectiveness was evaluated considering
the benefits and harms estimated using the GDG’s ad-hoc model
described above (Supplementary Fig. 3) and the costs reported by
the studies included in the literature review. Eight studies reported
costs for the use of the 21-RS in women with negative lymph
nodes,33–41 whereas three reported costs for women with up to





































































































































































































































































































































































































































Recommendations from the European Commission Initiative on Breast Cancer. . .
P Giorgi Rossi et al.
1506
EUR 3180 per patient in five out of the 11 studies included. These
costs did not show significant differences between countries or
over time. For the 70-GS, two studies reported costs of EUR 3153
per patient for the use of this assay in women with negative
lymph nodes.40,41
Certainty of evidence
The overall certainty of the evidence was rated as low to very low.
The main concerns across studies were risk of bias, indirectness of
trial populations and imprecision (Supplementary Tables 6 and 7).
The evidence was also downgraded for indirectness due to the
assumptions used for the model that implied the use of evidence
from one population in another population and from different
duration of follow-up across studies.
Evidence to decision frameworks
21-RS. The GDG judged the anticipated desirable effects (i.e. the
avoided chemotherapy treatments) of using the test to guide
chemotherapy to be large and the undesirable effects (i.e. increase
in recurrence) trivial, with very low certainty of the evidence. The
costs were considered large, though no cost-effectiveness study
was included. A negative impact on equity was considered a
potential concern (Table 4).
For women with HoR-positive, HER2-negative, node-negative
invasive breast cancer, the ECIBC GDG suggests the use of the 21-
RS to guide the use of chemotherapy (conditional recommenda-
tion, very low certainty of the evidence, Table 5). The recommen-
dation is conditional because the certainty of evidence was very
low and the downstream consequences of avoiding chemother-
apy were not quantified, thus making the balance of benefits and
harms difficult to determine, together with the large resource
(costs) requirements (Table 4, see also https://healthcare-quality.
jrc.ec.europa.eu/sites/default/files/Guidelines/EtDs/Updated/
ECIBC_GLs_EtD_21_gene_recurrence_score.pdf).
The GDG did not consider women with node-positive invasive
breast cancer in this recommendation, because they were not
included in the TAILORx trial,23 the main source for model
parameters. The GDG also stated that sub-populations with high
clinical risk (defined according to AdjuvantOnline!)24,25 may
experience larger net desirable consequences and provide a more
favourable cost-effectiveness profile (Fig. 1). On the other hand,
women with low clinical risk may experience smaller or no net
desirable consequences. Indirect evidence from the MINDACT trial
using the 70-GS supports that conclusion. In fact, in this trial there
are very small, if any, benefits from chemotherapy in low clinical
risk women, independently of the genomic risk.6
New relevant results have been published on the 21-RS since
the systematic review used for this recommendation was
conducted.45,46 Recent data from the TAILORx trial stratified by
age and clinical risk have been published.45 The authors suggest
that women below 50 with an intermediate genomic risk score
could have a benefit from adding chemotherapy to endocrine
therapy if their clinical risk is high but the absence of a dose
response and very imprecise effect estimates suggest that chance
could play a major role. Furthermore, the reported analysis
suggests that data for evaluating the potentially most efficient
two-step testing strategy is missing.47,48 Mariotto and colleagues49
showed that application of the 21-RS risk to decide whether or not
to provide chemotherapy would produce savings in the actual US
real clinical practice. Another analysis using the same data
Table 3. Anticipated outcomes for the comparison between the
70-gene signature assay testing strategy (intervention) and
comparator scenario (no testing) per 1000 women with hormone
receptor-positive, HER2-negative, lymph node-negative or up to







Treated women 270 501.4 −232
Distant disease 53 48 4.5
Disease free 100 93 7
Deaths 30 26 3.5
aAccording to supplementary Fig. 3a.
bAccording to supplementary Fig. 3b.
Table 4. Judgements by the Guideline Development Group (GDG) in Evidence to decision framework for the question: Should multigene tests be
used in patients who have hormone receptor-positive, HER-2 negative, lymph node-negative or up to 3 lymph nodes-positive invasive breast cancer
to guide the use of adjuvant chemotherapy?
21-gene recurrence score (limited to women
with negative lymph nodes)
70-gene signature assay
Low clinical risk High clinical risk
Problem Yes Yes Yes
Desirable effects Large Trivial Large
Undesirable effects Trivial Trivial Small
Certainty of evidence Very low Low Low






Balance of effects Probably favours the intervention Favours the comparison Probably favours the
intervention
Resources required Large costs Large costs Large savings
Certainty of evidence of required
resources
Very low Very low Very low
Cost effectiveness No included studies No included studies No included studies
Equity Probably reduced Probably reduced Probably reduced
Acceptability Varies Varies Varies
Feasibility Varies Varies Varies
Final recommendation Conditional in favour of the intervention Strong against intervention Conditional in favour of the
intervention
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indicates that savings would be much larger if testing would be
performed according to a two-step strategy.50 The GDG, for the
moment, judged that the new evidence is consistent with the
recommendation.
70-GS. In light of the results from the MINDACT trial,6 the GDG
decided to split the recommendation according to clinical risk of
the population under study (at low and high clinical risk, Table 5
and Fig. 1). In the low clinical risk group the GDG recommends
against using the 70-GS testing to guide the use of chemotherapy
(strong recommendation, very low certainty of the evidence) as
there are no apparent benefits and there are very large costs (EUR
3153 per patient) (https://healthcare-quality.jrc.ec.europa.eu/sites/
default/files/Guidelines/EtDs/Updated/ECIBC_GLs_EtD_70_gene_
testing_low_risk.pdf).
For women with HoR-positive, HER2-negative, node-negative or
up to 3 lymph nodes-positive invasive breast cancer at high
clinical risk, the ECIBC GDG suggests using the 70-GS test to guide
the use of chemotherapy. The judgments favoured the interven-
tion in the high clinical risk population due to the moderate
desirable effect, a balance that probably favours the use of 70-GS
testing, and the large savings (Table 4). The recommendation is
conditional mainly because of the low certainty of the evidence
about the effects. The GDG also stated that the proportion of
women with 2 or 3 positive lymph nodes was small,




Statement of principal findings
The ECIBC GDG suggests the use of 21-RS in lymph node-negative
women, recognising that benefits are probably larger in women at
high clinical risk and suggests the use of the 70-GS only for
women at high clinical risk.
Strengths and weaknesses of the study
The strength of the recommendations includes the ECIBC’s
adherence to the requirements for trustworthy development of
guidelines.51–53 Previously, we described some limitations of our
guidelines.11,54 The weakness of the deterministic decision tree
model used is that it is, to some extent, a simplistic approach and
some assumptions are questionable (i.e. negligible effects in low
clinical risk, same effects in studies with different duration of
follow-up). Furthermore, we did not actually quantify the side
effects of chemotherapy, considering that avoiding any unneces-
sary chemotherapy was a desirable effect.
Relation to other guidelines
NICE recently published guidance on multigene testing.55 The
panel decided to evaluate the evidence for the four commercially
available multigene tests included in the ECBIC question, and for
the IHC4+ C test.56,57 The NICE guidelines did not follow the
GRADE methodology and also had a different goal, i.e. deciding
which tests should be funded by the UK National Health Service.
The NICE 21-RS recommendation is similar to the ECIBC
recommendation, a conditional recommendation limited to those
patients in which the risk of distant recurrence is intermediate,
using a validated tool such as PREDICT58 or the Nottingham
Prognostic Index (Table 6). This approach is based on the
assumption that in some patients the clinical and pathological
prognostic parameters are consistent (low or high risk), and that
multigene testing does not provide additional information. In
particular, the NICE panel recommended against the use of the 70-
GS, based on cost-effectiveness considerations (Table 6). Unfortu-
nately, the NICE guideline does not allow comparison of our
estimates of desirable and undesirable health effects. Some
Table 5. European Commission Initiative on Breast Cancer guidelines development group recommendations on the use of multigene tests to guide
the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor-positive, HER-2 negative.
21-gene recurrence score 70-gene signature
Women with low clinical riska Women with high clinical riska
Recommendation For women with hormone receptor-
positive, HER2-negative, lymph node-
negative invasive breast cancer, the
ECIBC’s Guidelines Development Group
(GDG) suggests using the 21-gene
recurrence score to guide the use of
chemotherapy.
For women with hormone receptor-
positive, HER2-negative, lymph node-
negative or up to 3 lymph nodes-
positive invasive breast cancer at low
clinical risk, the ECIBC’s Guidelines
Development Group (GDG) recommends
not using the 70-gene signature test to
guide the use of chemotherapy.
For women with hormone receptor-
positive, HER2-negative, lymph node-
negative or up to 3 lymph nodes-
positive invasive breast cancer at high
clinical risk, the ECIBC’s Guidelines
Development Group (GDG) suggests
using the 70-gene signature test to
guide the use of chemotherapy.
Strength Conditional recommendation for the
intervention
Very low certainty of the evidence
Strong recommendation against the
intervention
Low certainty of the evidence
Conditional recommendation for the
intervention
Low certainty of the evidence
Sub-group
considerations
The GDG did not consider women with
node-positive invasive breast cancer to
be included in this recommendation.
Women with high clinical riska and low
genomic risk (larger tumour diameter
and higher grade) may experience larger
net desirable consequences and provide
a better cost-benefit profile.
Women with low clinical riska and high
genomic risk may experience smaller or
no net desirable consequences. Indirect
evidence from other gene based testing
(e.g. 70-gene signature) supports that
conclusion.
The proportion of women with 2 or 3
node-positive breast cancer was small,
so the results may be less clear in this
subgroup.
The proportion of women with 2 or 3
node-positive breast cancer was small,
so the results may be less clear in this
subgroup.
aFor definitions of low and high clinical risk, see Supplementary Table 8.
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Women HoR+, HER2–, T1
or T2, lymph node-
negative 
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Testing all strategy Two steps strategy: Clinical risk
assessment followed by multigene
testing only if clinical risk is high    
Two steps strategy: Clinical risk
assessment followed by
multigene testing only if clinical
risk is high
21-GENE RECURRENCE SCORE 70-GENE SIGNATURE
Fig. 1 Flow charts reporting the possible uses of 21-gene recurrence score and for the 70-gene signature test to guide the use of
adjuvant chemotherapy in patients with early invasive breast cancer, hormone receptor-positive, HER-2 negative. Two strategies are
proposed for 21-gene recurrence score, the first in which all women are tested for genomic risk assessment and treated accordingly, the second
in which only women with high clinical risk are tested for genomic assessment, while those at low clinical risk are referred to endocrine therapy
alone without genomic risk assessment. According to sub-group considerations reported by the GDG, the latter strategy is probably more cost
effective and women might experience larger net desirable consequences. For the 70-gene signature only a two-step strategy is proposed
where only women at high clinical risk are tested for genomic risk; testing women at low clinical risk is not recommended.
Table 6. Synopsis of American Society of Clinical Oncology (ASCO)59–61 and the UK National Institute for Health and Care Excellence (NICE)55
recommendations on 21-gene recurrence score and 70-gene signature assay in hormone receptor-positive, HER2-negative, lymph node-negative or
up to 3 nodes-positive invasive breast cancer.
ASCO58,60 NICE54
21-gene recurrence score
Low clinical risk Strong recommendation
High clinical risk Strong recommendation Recommended if: clinical risk is “intermediate” according to the
PREDICT tool53 or the Nottingham Prognostic Index, i.e. the
additional benefit of chemotherapy is between 3 and 5% increase in
survival, the decision on the therapy will depend on the test result,
the test is provided at reduced price.
Negative lymph nodes Strong recommendation Recommendation applies to both lymph node-negative patients
and lymph node-positive patients, restricted to micro-metastases1 to 3 positive lymph nodes Not recommended
ASCO60 NICE55
70-gene signature assay
Low clinical risk Strong against Recommendation against because not cost effective
High clinical risk Strong in favour
Negative lymph nodes Strong in favour
1 to 3 positive lymph nodes Moderate in favour
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methodological differences might explain the divergent results:
since real practice varies across Europe, we preferred to use
theoretical scenarios as comparators and interventions not
accounting for non-compliance, while the NICE model used real
practice as comparator (the prevalence of chemotherapy used in
this group of women in the UK), and as intervention (a change in
the probability of receiving chemotherapy given the test result).
Furthermore, the model used by NICE assumed that the tests are
only prognostically relevant but are not predictive of the response
to treatment, i.e. they calculated a constant HR of 0.77 for
chemotherapy in addition to endocrine therapy compared to
endocrine therapy alone in all risk groups. In contrast, the ECIBC
GDG judged the benefits to be trivial or small in the low clinical
risk group. Finally, for the 21-RS a commercial-in-confidence
discounted test cost was used to model cost-effectiveness, while
for the 70-GS the regular market price was used. It is worth noting
that despite NICE stating that the major benefit of the genetic
testing strategies would be a reduction of chemotherapy, the cost
models predict health benefits only if chemotherapy is increased.
The American Society of Clinical Oncology (ASCO) also provided
recommendations on the use of multigene tests.59–61 Despite a
different methodological approach, the direction of the recom-
mendations is the same, but the strength is not (Table 6). There
are differences in the grading of certainty of the evidence,
considered as high by the ASCO panellists, while the GDG valued
the evidence as very low for the 21-RS and low for the 70-GS.
Unfortunately, we were unable to deduce the details of the ASCO
evidence rating approach and also the criteria and judgments that
were used to determine the strength of the recommendations.
Unlike us, ASCO and NICE made recommendations on the 12-MS
and the PAM50-RORS to guide treatment decisions,55,62 mainly
because they did not exclude studies based on prognostic
results only.
Meaning of the study
The implications of our recommendations are context dependent.
The criteria used for making decisions on the provision or not of
adjuvant treatment differ between countries. Therefore, the cost-
benefit profile of introducing one of the multigene tests might
also vary across countries. Decreasing costs for the tests would
support a more widespread use. For these considerations, the
GDG decided not to establish a threshold of recurrence risk to
recommend genomic risk assessment, or a threshold for adding
adjuvant chemotherapy, since these thresholds are context
specific.
In conclusion, the ECIBC GDG recommendations for or against
the use of 21-RS and 70-RS are justified based on the judgments
made. The transparency of our approach allows understanding
the rationale for making different recommendations for the two
tests and risk groups.
Unanswered questions and future research
Data protection issues may be of relevance for the 21-RS because
processing of samples is centralised in one US lab and requires
shipping samples abroad. Furthermore, transparent information
on test results is not available and reproducibility has been
questioned.63
The GDG recommends research on exploring in what sub-
groups the use of 21-RS would have larger anticipated benefits as
well as carrying out longer follow-up studies for 70-GS. The
recommendations will be updated according to the ECIBC mon-
itoring strategy in place (https://healthcare-quality.jrc.ec.europa.
eu/discover-ecibc/methodologies/guidelines-updating).
Furthermore, the GDG is exploring the possibility of evaluating
biomarkers that may assist decision making regarding the
administration of adjuvant chemotherapy on the basis of their
ability to identify women with a sufficiently low risk of relapse that
would allow them to be spared from chemotherapy. In contrast to
the presented evidence evaluation, this would enable evidence-
based and transparent recommendations based on prognostic
cohort studies, randomised or not, that predict the recurrence risk
of different subgroups. We are currently working on a healthcare
question on the significance of Ki67 using this strategy. In a next
step, such an approach might also make it possible to evaluate
multigene tests in the assessment for which we found no usable
evidence in the predictive search strategy used here, but for which
data on the prognostic value are available.13–17,64
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